Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.

Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.

The highly immunogenic human tumor antigen NY-ESO-1 (ESO) is a target of choice for anti-cancer immune therapy. In this study, we assessed spontaneous antibody (Ab) responses to ESO in a large cohort of patients with primary breast cancer (BC) and addressed the correlation between the presence of an...

Full description

Bibliographic Details
Main Authors: Ahmed Hamaï, Karine Duperrier-Amouriaux, Pascale Pignon, Isabelle Raimbaud, Lorenzo Memeo, Cristina Colarossi, Vincenzo Canzonieri, Tiziana Perin, Jean-Marc Classe, Mario Campone, Pascal Jézéquel, Loïc Campion, Maha Ayyoub, Danila Valmori
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3117860?pdf=render

Internet

http://europepmc.org/articles/PMC3117860?pdf=render

Similar Items